Vimarsana
Biggest News Aggregation in the World

Page 5 - Nasdaq Bbio News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq Bbio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Bbio Today - Breaking & Trending Today

Panagora Asset Management Inc. Takes $2.41 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Vimarsana News

Panagora Asset Management Inc. Takes $2.41 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Panagora Asset Management Inc. acquired a new position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 140,245 shares of the company’s stock, valued at approximately $2,412,000. Panagora Asset Management Inc. owned 0.09% of BridgeBio […]

Source: wkrb13.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by E Fund Management Co. Ltd. - Vimarsana News

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Bought by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. raised its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 83.5% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,916 shares of the company’s stock after acquiring an additional 12,700 shares during […]

BridgeBio Pharma Presents Additional Clinical Outcomes Data - Vimarsana News

BridgeBio Pharma Presents Additional Clinical Outcomes Data

- As previously announced, the primary endpoint (a hierarchical analysis inclusive of all-cause mortality and frequency of cardiovascular-related...

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $37.30 Average Price Target from Analysts - Vimarsana News

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives $37.30 Average Price Target from Analysts

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ten analysts that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating on the company. The average twelve-month price target […]

Moody Aldrich Partners LLC Sells 64,980 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - Vimarsana News

Moody Aldrich Partners LLC Sells 64,980 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Moody Aldrich Partners LLC lessened its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 44.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 79,873 shares of the company’s stock after selling 64,980 shares during the period. Moody […]

Source: wkrb13.com